These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1033 related articles for article (PubMed ID: 34920118)

  • 1. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
    Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
    Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanisms of resistance and escape to CAR-T cells].
    Grinda T; Brouard J; Tran D; Rubio MT
    Bull Cancer; 2021 Oct; 108(10S):S128-S140. PubMed ID: 34920795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
    Tahmasebi S; Elahi R; Esmaeilzadeh A
    Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene modification strategies for next-generation CAR T cells against solid cancers.
    Tian Y; Li Y; Shao Y; Zhang Y
    J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?
    Amorós-Pérez B; Rivas-Pardo B; Gómez Del Moral M; Subiza JL; Martínez-Naves E
    Cells; 2024 Apr; 13(9):. PubMed ID: 38727261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.
    Rodriguez-Garcia A; Palazon A; Noguera-Ortega E; Powell DJ; Guedan S
    Front Immunol; 2020; 11():1109. PubMed ID: 32625204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.
    Andrea AE; Chiron A; Mallah S; Bessoles S; Sarrabayrouse G; Hacein-Bey-Abina S
    Front Immunol; 2022; 13():830292. PubMed ID: 35211124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.
    Bell M; Gottschalk S
    Front Immunol; 2021; 12():684642. PubMed ID: 34177932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
    Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
    Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward.
    Jafarzadeh L; Masoumi E; Fallah-Mehrjardi K; Mirzaei HR; Hadjati J
    Front Immunol; 2020; 11():702. PubMed ID: 32391013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors.
    Ghahri-Saremi N; Akbari B; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
    Front Immunol; 2021; 12():738456. PubMed ID: 34721401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
    Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V
    J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.